Abstract
The amyloid precursor protein (APP) has previously been allocated to an organellar pool residing in the Golgi apparatus and in endosomal compartments, and in its mature form to a presynaptic active zone-localized pool. By analyzing homozygous APP knockout mice we evaluated the impact of APP on synaptic vesicle protein abundance at synaptic release sites. Following immunopurification of synaptic vesicles and the attached presynaptic plasma membrane, individual proteins were subjected to quantitative Western blot analysis. We demonstrate that APP deletion in knockout animals reduces the abundance of the synaptic vesicle proteins synaptophysin, synaptotagmin-1, and SV2A at the presynaptic active zone. Conversely, deletion of the additional APP family members, APLP1 and APLP2 resulted in an increase in synaptophysin, synaptogamin-1, and SV2A abundance. When transmembrane APP is lacking in APPsα-KI/APLP2-KO mice synaptic vesicle protein abundance corresponds to that in APP -KO mice. Deletion of the synaptic vesicle protein 2 (SV2) A and B had no effect on APP and synaptophysin abundance but decreased synaptotagmin-1. Our data suggest that APP controls the abundance of synaptic vesicle proteins at the presynaptic release sites and thus impacts synaptic transmission.
Keywords: Amyloid precursor protein APP, APLP1, APLP2, docked synaptic vesicles, presynaptic active zone, SV2, synaptotagmin- 1, synaptophysin.
Current Alzheimer Research
Title:Amyloid Precursor Protein Knockout Diminishes Synaptic Vesicle Proteins at the Presynaptic Active Zone in Mouse Brain
Volume: 11 Issue: 10
Author(s): Melanie Laßek, Jens Weingarten, Amparo Acker-Palmer, Sandra M. Bajjalieh, Ulrike Muller and Walter Volknandt
Affiliation:
Keywords: Amyloid precursor protein APP, APLP1, APLP2, docked synaptic vesicles, presynaptic active zone, SV2, synaptotagmin- 1, synaptophysin.
Abstract: The amyloid precursor protein (APP) has previously been allocated to an organellar pool residing in the Golgi apparatus and in endosomal compartments, and in its mature form to a presynaptic active zone-localized pool. By analyzing homozygous APP knockout mice we evaluated the impact of APP on synaptic vesicle protein abundance at synaptic release sites. Following immunopurification of synaptic vesicles and the attached presynaptic plasma membrane, individual proteins were subjected to quantitative Western blot analysis. We demonstrate that APP deletion in knockout animals reduces the abundance of the synaptic vesicle proteins synaptophysin, synaptotagmin-1, and SV2A at the presynaptic active zone. Conversely, deletion of the additional APP family members, APLP1 and APLP2 resulted in an increase in synaptophysin, synaptogamin-1, and SV2A abundance. When transmembrane APP is lacking in APPsα-KI/APLP2-KO mice synaptic vesicle protein abundance corresponds to that in APP -KO mice. Deletion of the synaptic vesicle protein 2 (SV2) A and B had no effect on APP and synaptophysin abundance but decreased synaptotagmin-1. Our data suggest that APP controls the abundance of synaptic vesicle proteins at the presynaptic release sites and thus impacts synaptic transmission.
Export Options
About this article
Cite this article as:
Laßek Melanie, Weingarten Jens, Acker-Palmer Amparo, Bajjalieh M. Sandra, Muller Ulrike and Volknandt Walter, Amyloid Precursor Protein Knockout Diminishes Synaptic Vesicle Proteins at the Presynaptic Active Zone in Mouse Brain, Current Alzheimer Research 2014; 11 (10) . https://dx.doi.org/10.2174/1567205011666141107152458
DOI https://dx.doi.org/10.2174/1567205011666141107152458 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Alzheimer's Disease Drug Development
Alzheimer's disease is a progressive neurodegenerative disorder that affects millions of people worldwide. Despite decades of research, no cure or disease-modifying treatment is available yet. Therefore, the need for developing effective therapies to treat Alzheimer's disease is an urgent matter. This special issue aims to provide a comprehensive overview of ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
NAChR α4β2 Subtype and their Relation with Nicotine Addiction, Cognition, Depression and Hyperactivity Disorder
Current Medicinal Chemistry In vitro Antioxidant and Acetylcholinesterase Inhibitory Activities of Fractions from Centella asiatica (Linn.) Extract
Current Bioactive Compounds Molecular Effects of L-dopa Therapy in Parkinson’s Disease
Current Genomics Pleiotropic Effects of Simvastatin on Some Calcium Regulatory and Myofibrillar Proteins in Ischemic/Reperfused Heart: Causality of Statins Cardioprotection?
Current Pharmaceutical Design Plasma Indoleamine-2,3-Dioxygenase (IDO) is Increased in Drug-Naï ve Major Depressed Patients and Treatment with Sertraline and Ketoprofen Normalizes IDO in Association with Pro-Inflammatory and Immune- Regulatory Cytokines
CNS & Neurological Disorders - Drug Targets Depression Rises the Risk of Hypertension Incidence: Discussing the Link through the Ca2+/cAMP Signalling
Current Hypertension Reviews Exploring the Potential of Neuroproteomics in Alzheimer's Disease
Current Topics in Medicinal Chemistry p35 Deficiency Accelerates HMGB-1-mediated Neuronal Death in the Early Stages of an Alzheimer's disease Mouse Model
Current Alzheimer Research Genetic Association Analysis of NOS3 and Methamphetamine-Induced Psychosis Among Japanese
Current Neuropharmacology Development of Novel Amyloid Imaging Agents Based Upon Thioflavin S
Current Alzheimer Research Selective Elevation of Circulating CCL2/MCP1 Levels in Patients with Longstanding Post-vaccinal Macrophagic Myofasciitis and ASIA
Current Medicinal Chemistry COPD Evaluation: Beyond the Airway Obstruction, a Follow Up
Current Respiratory Medicine Reviews Melatonin and Renal Protection: Novel Perspectives from Animal Experiments and Human Studies (Review)
Current Pharmaceutical Design Mitochondrial Dysfunction and Its Relationship with mTOR Signaling and Oxidative Damage in Autism Spectrum Disorders
Mini-Reviews in Medicinal Chemistry Commentary: Research Highlights ATF4: The Perpetrator in Axonal-Mediated Neurodegeneration in Alzheimer's Disease
CNS & Neurological Disorders - Drug Targets VIP and Drug Design
Current Pharmaceutical Design Curcumin Nanomedicine: A Road to Cancer Therapeutics
Current Pharmaceutical Design An Old Drug with a New Purpose: Cardiovascular Actions of Acetaminophen (Paracetamol)
Current Drug Targets - Cardiovascular & Hematological Disorders Functional Selectivity in Cannabinoid Signaling
Current Molecular Pharmacology Recombinant Hepatitis B Vaccination in Renal Failure Patients
Current Pharmaceutical Biotechnology